BloodJClub
Combining quizartinib with intensive chemotherapy for older patients with newly diagnosed AML: results of the UK NCRI AML18 trial.
Blood · · Randomized Controlled Trial · Open access
Knapper, Thomas + more
Abstract ↗AI summary
The abstract is read at the publisher; the summary is JClub's.
In older patients (>60) with newly diagnosed AML, adding quizartinib to intensive chemotherapy improved overall survival only for FLT3-mutated disease (HR 0.59, 95% CI 0.37–0.93).
- Why it matters: The trial addressed whether quizartinib could improve outcomes beyond intensive chemotherapy in older adults, including those without FLT3 mutations, where benefit was uncertain.
- What they did: In the UK NCRI AML18 randomized trial, 463 patients received quizartinib 40 mg or control for 14 days after chemotherapy courses 2 and 3 plus 28 additional days, with further randomization to long versus short maintenance.
- The result: Quizartinib increased non-relapse mortality overall, showed no survival or relapse benefit in FLT3-WT patients, but reduced relapse risk and improved OS in FLT3-mutated patients, especially with short maintenance.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.
- Open access